688185:SSECanSino Biologics, Inc. Class A Analysis
Data as of 2026-08-24 - not real-time
CN¥77.28
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
CanSino Biologics Inc. is priced at ¥77.28, and its moving averages give no clean directional read — the structure is neutral. The last 30 days have gained 55.8%. With RSI at 81.6 the momentum picture is overbought, alongside a bullish MACD signal. Watch ¥48.38 as support and ¥80.00 as the nearer resistance level.
Valuation screens as overvalued: a P/E of 702.5 sits above the sector average of 31.1. Consensus targets land 3.5% above where the shares trade now. Revenue is growing at 38.7% on a -0.1% profit margin.
On a 1-10 scale the risk profile lands at 7 — elevated. With 30-day volatility of 83.6%, a beta of 0.26 and a maximum drawdown of 45.7%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Near-term and long-term part ways here — hold short-term against sell longer out, with 4/10 conviction on the long call.
Valuation screens as overvalued: a P/E of 702.5 sits above the sector average of 31.1. Consensus targets land 3.5% above where the shares trade now. Revenue is growing at 38.7% on a -0.1% profit margin.
On a 1-10 scale the risk profile lands at 7 — elevated. With 30-day volatility of 83.6%, a beta of 0.26 and a maximum drawdown of 45.7%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Near-term and long-term part ways here — hold short-term against sell longer out, with 4/10 conviction on the long call.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 2/10
Key Factors
- RSI at 81.6 signals overbought conditions
- Trading above the 200-day average of 63.17
- MACD momentum is positive
Medium Term
1–3 yearsNeutral
Model confidence: 3/10
Key Factors
- RSI at 81.6 signals overbought conditions
- P/E of 702.5 versus sector average of 31.1
- Trading above the 200-day average of 63.17
Long Term
> 3 yearsCautious
Model confidence: 4/10
Key Factors
- P/E of 702.5 versus sector average of 31.1
- Negative profit margin of -0.1%
- Negative return on equity of -0.0%
Key Metrics & Analysis
Financial Health
Revenue Growth38.70%
Profit Margin-0.09%
P/E Ratio702.5
ROE-0.02%
ROA-0.83%
Debt/Equity23.59
P/B Ratio3.9
Op. Cash FlowCN¥37.8M
Free Cash FlowCN¥-351570848
Industry P/E31.1
Technical Analysis
TrendNeutral
RSI81.6
SupportCN¥48.38
ResistanceCN¥80.00
MA 20CN¥56.06
MA 50CN¥52.77
MA 200CN¥63.17
MACDBullish
VolumeIncreasing
Fear & Greed Index94.41
Valuation
Fair ValueCN¥8.79
Target PriceCN¥80.00
Upside/Downside3.52%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta0.26
Volatility83.57%
Sector RiskMedium
Reg. RiskHigh
Geo RiskHigh
Currency RiskHigh
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.